An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)

NCT01202058 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

156

Enrollment

INDUSTRY

Sponsor class

Stopped The NEVO™ stent will not be commercialized. Cordis decided to close the study after 1 years. This decision took the absence of safety signals into account.

Conditions

Atherosclerotic Coronary Artery Disease

Interventions

DEVICE: NEVO™ Sirolimus-eluting Coronary Stent System
DEVICE: XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)

Sponsor

Cordis US Corp.